Sensory deprivation is a risk factor for cognitive decline and dementia, but will correcting impaired hearing and vision prevent these outcomes? Yes, these studies suggest. Medscape Medical News
Month: October 2018
Anatomic results maintained at end of brolucizumab studies
CHICAGO — Brolucizumab maintained non-inferiority to aflibercept regarding best corrected visual acuity change at week 96, which was the end of the HAWK and HARRIER trials, according to a speaker.In both trials, the primary endpoint of non-inferiority …
Veinplicity Makes Veins Fatter for Easier Access (Interview)
Venous access is famously difficult in many patients, and devices have been developed in the past to make veins easier to see. Seeing narrow veins doesn’t make it much easier to get inside of them, but the Veinplicity device from Physeon, a Swiss company that’s part of Germany’s Novintum Medical Technology, actually makes veins more engorged […]
Microfluidic Device to Study How Pancreatic Cancer Develops Clots
Using lab animals in medical science is not only an ethical issue, but the research findings often don’t match up to what happens in humans. Simulating various natural processes within microfluidic devices often a provides a more reliable, and easier to work with, laboratory technique over live animals. Researchers at Purdue University have built a microfluidic […]
VIDEO: ForeseeHome helps monitor AMD progression
CHICAGO — Lisa K. Feulner, MD, PhD, discusses the importance of early detection of a transition from dry to wet age-related macular degeneration and how the ForeseeHome program (Notal Vision) has helped her patients monitor progression at home at the A…
AMA announces new initiative supporting ‘meaningful improvements’ to residency training
AMA recently announced that it will award $15 million in grant funding over the next 5 years to training programs that discuss the changing needs of patients, communities and the workforce needs of the current and future health care system.AMA leaders …
GE Healthcare fetalHQ Automatic Fetal Heart Assessment Tool
About the size of a grape, a baby’s heart at five months of gestation is very difficult to image using ultrasound. Moreover, because it beats considerably faster than adult hearts, recognizing its size and shape with one’s eyes can be even more of a challenge. GE Healthcare is now addressing this issue with its fetalHQ software […]
Surgeon advocates early referral for pediatric cross-linking
CHICAGO — Corneal cross-linking should be considered in pediatric patients at diagnosis of clinically identifiable keratoconus, a speaker here said.Even though FDA approval of the Avedro treatment system is indicated for progressive keratoconus in pati…
VIDEO: Wavefront-guided, wavefront-optimized platforms both effective for LASIK
CHICAGO — At the American Academy of Ophthalmology meeting here, Edward Manche, MD, discusses a study comparing wavefront-guided and wavefront-optimized LASIK surgery.
Researchers find key differences in brains of males and females with schizophrenia
Researchers from the Icahn School of Medicine at Mount Sinai have found clear disparities in the way males and females–both those with schizophrenia and those who are healthy–discern the mental states of others.
Tocilizumab reduces haze, increases visual acuity in noninfectious uveitis
CHICAGO — Repeated intravitreal injections of tocilizumab 4 mg/kg and 8 mg/kg in patients with noninfectious uveitis improved visual acuity and reduced vitreous haze at 6 months, according to a speaker here.Muhammad Hassan, MD, said intravitreal inject…
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Epidemiology Forecast 2016-2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Epidemiology Forecast-2027” report has been added to ResearchAndMarkets.com’s offering. Neuromyelitis Optica Spectrum Disorder (NMOSD) – Epidemiology Forecast-2027′ report d…
Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will releas…
CooperVision’s Contacts Combat Eye Fatigue from Digital Screen Usage (Interview)
A recent study by OnePoll, conducted on behalf of CooperVision, manufacturer of soft contact lenses, found that 49 percent of Americans “feel society has become more digital and screen-oriented in the past five years.” The trend is not unexpected with 74 percent of employed Americans using a computer at their job and 7 in 10 […]
Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release,…
Worldwide Analysis on the Nonmydriatic Handheld Fundus Camera Market (2018-2025) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Nonmydriatic Handheld Fundus Camera Market Analysis Report By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), And Segment Forecasts, 2018 – 2025” report has been added to ResearchAndMarke…
Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TE…
Low-dose atropine effective in slowing myopia progression
CHICAGO — Low doses of atropine are the most effective in slowing myopia progression, according to a speaker here.Multiple studies comparing different doses of atropine have shown a 0.01% dose has slowed myopia progression more so than doses of 0.05% o…
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences today announced that updated data from its Phase 1b/2 trial evaluating the safety and efficacy of light-activated AU-011 was highlighted in an oral presentation at AAO 2018.
Retinal malpractice issues involve ROP, injections and wrong events
CHICAGO — Even though malpractice lawsuits for retinopathy of prematurity are rare, they are expensive, according to AAO President-elect George A. Williams, MD.Williams, who is chair of the board of Ophthalmic Mutual Insurance Company, delivered pearls…